The Helicobacter pylori eradication in the group receiving standard -dose and group continue taking amoxicillin for 4 weeks; a clinical trial study
- PMID: 26171138
- PMCID: PMC4495427
The Helicobacter pylori eradication in the group receiving standard -dose and group continue taking amoxicillin for 4 weeks; a clinical trial study
Abstract
Aim: The aim of this study was to evaluate the Helicobacter pylori eradication in the group receiving standard -dose twice a day for two weeks and continue taking amoxicillin for 4 weeks.
Background: Helicobacter pylori is the major etiological cause of chronic gastritis, gastric and duodenal ulcers, gastric cancer and lymphoma. Therefore, patients should be treated after diagnosis of H. pylori infection.
Patients and methods: A total of 66 consecutive patients with rapid urease test during endoscopy or biopsy positive for H. pylori were enrolled in this clinical trial study during 2013-2014. Patients were divided randomly into two groups. Group A (standard dose) received omeprazole (20 mg), amoxicillin (1 g), and clarithromycin (500 mg), all two times a day for two weeks. Group B received standard dose like group A and in patients with H.pylori infection amoxicillin were continued for 4 weeks. After completion of treatment, patients did not receive any treatment for a month and then stool antigen was performed to evaluate the H.pylori.
Results: The rate of successful HP eradication was significantly higher in group A (90.9% V.s 63.6%; p=0.017). Inflation and bitter mouth were found in 8 and 13 patients in group A and 7 and 9 patients in group B, respectively. The incidence of adverse effects was the same (p=0.437).
Conclusion: Increased duration of antibiotic therapy to four weeks significantly raises the rate of successful HP eradication with standard triple therapy without significant increase in adverse effects.
Keywords: Amoxicillin; Clarithromycin; Helicobacter pylori; Omeprazole.
Similar articles
-
[Effects of different triple therapies on duodenal ulcer-associated Helicobacter pylori infection and a one-year follow-up study].Zhonghua Yi Xue Za Zhi. 2004 Jul 17;84(14):1161-5. Zhonghua Yi Xue Za Zhi. 2004. PMID: 15387976 Clinical Trial. Chinese.
-
Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial.Turk J Gastroenterol. 2013;24(1):10-4. doi: 10.4318/tjg.2013.0540. Turk J Gastroenterol. 2013. PMID: 23794338 Clinical Trial.
-
Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study.Ter Arkh. 2018 Aug 27;90(8):27-32. doi: 10.26442/terarkh201890827-32. Ter Arkh. 2018. PMID: 30701936 Clinical Trial.
-
Are twelve days of omeprazole, amoxicillin and clarithromycin better than six days for treating H. pylori infection in peptic ulcer and in non-ulcer dyspepsia?Hepatogastroenterology. 2001 Sep-Oct;48(41):1383-8. Hepatogastroenterology. 2001. PMID: 11677970
-
Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients.World J Gastroenterol. 2005 Apr 28;11(16):2477-81. doi: 10.3748/wjg.v11.i16.2477. World J Gastroenterol. 2005. PMID: 15832421 Free PMC article. Clinical Trial.
Cited by
-
Eradication of Helicobacter Pylori in Iran: A Review.Middle East J Dig Dis. 2018 Jan;10(1):5-17. doi: 10.15171/mejdd.2017.84. Epub 2017 Sep 21. Middle East J Dig Dis. 2018. PMID: 29682242 Free PMC article. Review.
-
Comparison of Helicobacter pylori eradication regimens in patients with end stage renal disease.Gastroenterol Hepatol Bed Bench. 2018 Winter;11(1):15-19. Gastroenterol Hepatol Bed Bench. 2018. PMID: 29564060 Free PMC article.
References
-
- NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994;272:65–69. - PubMed
-
- Khedmat H, Ahmadzad-Asl M, Amini M, Lessan-Pezeshki M, Einollahi B, Pourfarziani V, et al. Gastro-duodenal lesions and Helicobacter pylori infection in uremic patients and renal transplant recipients. Transplant Proc. 2007;39:1003–7. - PubMed
-
- Blaser MJ, Atherton JC. In: Helicobacter pylori infections. 17th ed. Fauci AS, Braunwald E, Kasper DL, et al., editors. New York: McGraw-Hill; 2008.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous